Clinical use of insulin degludec

Jiten Vora, Bertrand Cariou, Marc Evans, Jorge Luiz Gross, Stewart Harris, Lena Landstedt-Hallin, Ambrish Mithal, Martín Rodríguez Rodriguez, Luigi Meneghini

Research output: Contribution to journalReview article

39 Scopus citations

Abstract

The limitations of current basal insulin preparations include concerns related to their pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and perception of management complexity, including rigid dosing schedules. Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties compared to insulin glargine (IGlar) including a long half-life of ~25. h and a duration of action >42. h at steady state, providing a flat and stable blood glucose-lowering effect when injected once daily. Evidence from phase 3a clinical trials with a treat-to-target design in patients with type 1 and type 2 diabetes has shown that IDeg has similar efficacy to IGlar, with a 9% and 26% reduction in risk of overall and nocturnal hypoglycaemia, respectively (in the pooled population) during the entire treatment period, and a 16% and 32% reduction during the maintenance period, respectively. Given its pharmacodynamic properties, IDeg offers a broad dosing window, allowing for flexible dose administration, if required. Two different formulations of IDeg are available (100. units/mL [U100] and 200. units/mL), the latter providing the same IDeg dose as the U100 formulation in half the injection volume. The unique pharmacokinetic profile of IDeg facilitates glycaemic control while minimising the risk of nocturnal hypoglycaemia.

Original languageEnglish (US)
Pages (from-to)19-31
Number of pages13
JournalDiabetes research and clinical practice
Volume109
Issue number1
DOIs
StatePublished - Jul 1 2015

Keywords

  • Clinical practice
  • Diabetes
  • Dosing
  • Hypoglycaemia
  • Insulin
  • Insulin degludec

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Clinical use of insulin degludec'. Together they form a unique fingerprint.

  • Cite this

    Vora, J., Cariou, B., Evans, M., Gross, J. L., Harris, S., Landstedt-Hallin, L., Mithal, A., Rodriguez, M. R., & Meneghini, L. (2015). Clinical use of insulin degludec. Diabetes research and clinical practice, 109(1), 19-31. https://doi.org/10.1016/j.diabres.2015.04.002